Breaking News, Collaborations & Alliances

Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

Will equally share future profits in the U.S.

Author Image

By: Charlie Sternberg

Associate Editor

Cullinan Oncology Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, has completed its agreement with Taiho Pharmaceutical Co., Ltd. signed in May 2022. Per the terms of the agreement, the companies will collaborate on the U.S. development of CLN-081/TAS6417, a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC).   Taiho has a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters